Researchers have applied CC with the PAM50 gene set as features to categorize molecular subtypes of breast cancer based on expression profiles, dividing them into luminal, triple-negative, and Her2-positive subtypes, and have developed corresponding treatment strategies based on these classifications [42]. This evidence concerns the gene ERBB2 and breast carcinoma.